+1 (704) 266-3234

Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, Status And Forecast 2021-2027

Published on: Jul 2021 | From USD $3900 | Published By: QY RESEARCH | Number Of Pages: 109

Devicís syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.

Market Analysis and Insights: Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market
The global Devicís Syndrome (Neuromyelitis Optica) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Devicís Syndrome (Neuromyelitis Optica) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Devicís Syndrome (Neuromyelitis Optica) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Devicís Syndrome (Neuromyelitis Optica) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Devicís Syndrome (Neuromyelitis Optica) Treatment market.

Global Devicís Syndrome (Neuromyelitis Optica) Treatment Scope and Market Size
Devicís Syndrome (Neuromyelitis Optica) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Devicís Syndrome (Neuromyelitis Optica) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab

Segment by Application
Hospitals
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Eculizumab
1.2.3 Methylprednisolone
1.2.4 Azathioprine
1.2.5 Mycophenolate Mofetil
1.2.6 Rituximab
1.3 Market by Application
1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2016-2027)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Regions
2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Dynamic
2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue
3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2016-2021)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2020
3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.6 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.7 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2022-2027)

5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
6.2.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
6.2.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
6.2.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
6.3.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
6.3.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
6.3.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
6.4.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
6.4.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
7.2.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
7.3.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
7.4.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
8.2.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
8.3.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region
8.4.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
9.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
9.2.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
9.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
9.3.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
9.4 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
9.4.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
10.2.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
10.3.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
10.4.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Alexion Pharmaceuticals, Inc.
11.1.1 Alexion Pharmaceuticals, Inc. Company Details
11.1.2 Alexion Pharmaceuticals, Inc. Business Overview
11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.1.5 Alexion Pharmaceuticals, Inc. Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Fresenius Kabi AG
11.3.1 Fresenius Kabi AG Company Details
11.3.2 Fresenius Kabi AG Business Overview
11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.3.5 Fresenius Kabi AG Recent Development
11.4 Pharmacia & Upjohn (a subsidary of Pfizer)
11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
11.5 Lupin Ltd.
11.5.1 Lupin Ltd. Company Details
11.5.2 Lupin Ltd. Business Overview
11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.5.5 Lupin Ltd. Recent Development
11.6 Sagent Pharmaceuticals, Inc.
11.6.1 Sagent Pharmaceuticals, Inc. Company Details
11.6.2 Sagent Pharmaceuticals, Inc. Business Overview
11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.6.5 Sagent Pharmaceuticals, Inc. Recent Development
11.7 Zydus Pharmaceuticals, Inc.
11.7.1 Zydus Pharmaceuticals, Inc. Company Details
11.7.2 Zydus Pharmaceuticals, Inc. Business Overview
11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.7.5 Zydus Pharmaceuticals, Inc. Recent Development
11.8 Sandoz Inc. (Novartis)
11.8.1 Sandoz Inc. (Novartis) Company Details
11.8.2 Sandoz Inc. (Novartis) Business Overview
11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.8.5 Sandoz Inc. (Novartis) Recent Development
11.9 Alkem Laboratories Ltd.
11.9.1 Alkem Laboratories Ltd. Company Details
11.9.2 Alkem Laboratories Ltd. Business Overview
11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.9.5 Alkem Laboratories Ltd. Recent Development
11.10 Mylan Pharmaceuticals, Inc.
11.10.1 Mylan Pharmaceuticals, Inc. Company Details
11.10.2 Mylan Pharmaceuticals, Inc. Business Overview
11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.10.5 Mylan Pharmaceuticals, Inc. Recent Development
11.11 Hoffmann-La Roche/ Chugai Pharmaceutical
11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
11.12 MedImmune LLC
11.12.1 MedImmune LLC Company Details
11.12.2 MedImmune LLC Business Overview
11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.12.5 MedImmune LLC Recent Development
11.13 RemeGen, Ltd.
11.13.1 RemeGen, Ltd. Company Details
11.13.2 RemeGen, Ltd. Business Overview
11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.13.5 RemeGen, Ltd. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Eculizumab
Table 3. Key Players of Methylprednisolone
Table 4. Key Players of Azathioprine
Table 5. Key Players of Mycophenolate Mofetil
Table 6. Key Players of Rituximab
Table 7. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2016-2021)
Table 11. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2022-2027)
Table 13. Devicís Syndrome (Neuromyelitis Optica) Treatment Market Trends
Table 14. Devicís Syndrome (Neuromyelitis Optica) Treatment Market Drivers
Table 15. Devicís Syndrome (Neuromyelitis Optica) Treatment Market Challenges
Table 16. Devicís Syndrome (Neuromyelitis Optica) Treatment Market Restraints
Table 17. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Players (2016-2021)
Table 19. Global Top Devicís Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment as of 2020)
Table 20. Ranking of Global Top Devicís Syndrome (Neuromyelitis Optica) Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Devicís Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
Table 24. Date of Enter into Devicís Syndrome (Neuromyelitis Optica) Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Alexion Pharmaceuticals, Inc. Company Details
Table 65. Alexion Pharmaceuticals, Inc. Business Overview
Table 66. Alexion Pharmaceuticals, Inc. Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 67. Alexion Pharmaceuticals, Inc. Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 68. Alexion Pharmaceuticals, Inc. Recent Development
Table 69. Teva Pharmaceuticals Company Details
Table 70. Teva Pharmaceuticals Business Overview
Table 71. Teva Pharmaceuticals Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 72. Teva Pharmaceuticals Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 73. Teva Pharmaceuticals Recent Development
Table 74. Fresenius Kabi AG Company Details
Table 75. Fresenius Kabi AG Business Overview
Table 76. Fresenius Kabi AG Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 77. Fresenius Kabi AG Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 78. Fresenius Kabi AG Recent Development
Table 79. Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
Table 80. Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
Table 81. Pharmacia & Upjohn (a subsidary of Pfizer) Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 82. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 83. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
Table 84. Lupin Ltd. Company Details
Table 85. Lupin Ltd. Business Overview
Table 86. Lupin Ltd. Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 87. Lupin Ltd. Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 88. Lupin Ltd. Recent Development
Table 89. Sagent Pharmaceuticals, Inc. Company Details
Table 90. Sagent Pharmaceuticals, Inc. Business Overview
Table 91. Sagent Pharmaceuticals, Inc. Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 92. Sagent Pharmaceuticals, Inc. Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 93. Sagent Pharmaceuticals, Inc. Recent Development
Table 94. Zydus Pharmaceuticals, Inc. Company Details
Table 95. Zydus Pharmaceuticals, Inc. Business Overview
Table 96. Zydus Pharmaceuticals, Inc. Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 97. Zydus Pharmaceuticals, Inc. Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 98. Zydus Pharmaceuticals, Inc. Recent Development
Table 99. Sandoz Inc. (Novartis) Company Details
Table 100. Sandoz Inc. (Novartis) Business Overview
Table 101. Sandoz Inc. (Novartis) Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 102. Sandoz Inc. (Novartis) Recent Development
Table 103. Alkem Laboratories Ltd. Company Details
Table 104. Alkem Laboratories Ltd. Business Overview
Table 105. Alkem Laboratories Ltd. Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 106. Alkem Laboratories Ltd. Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 107. Alkem Laboratories Ltd. Recent Development
Table 108. Mylan Pharmaceuticals, Inc. Company Details
Table 109. Mylan Pharmaceuticals, Inc. Business Overview
Table 110. Mylan Pharmaceuticals, Inc. Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 111. Mylan Pharmaceuticals, Inc. Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 112. Mylan Pharmaceuticals, Inc. Recent Development
Table 113. Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
Table 114. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
Table 115. Hoffmann-La Roche/ Chugai Pharmaceutical Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 116. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 117. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
Table 118. MedImmune LLC Company Details
Table 119. MedImmune LLC Business Overview
Table 120. MedImmune LLC Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 121. MedImmune LLC Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 122. MedImmune LLC Recent Development
Table 123. RemeGen, Ltd. Company Details
Table 124. RemeGen, Ltd. Business Overview
Table 125. RemeGen, Ltd. Devicís Syndrome (Neuromyelitis Optica) Treatment Product
Table 126. RemeGen, Ltd. Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 127. RemeGen, Ltd. Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Eculizumab Features
Figure 3. Methylprednisolone Features
Figure 4. Azathioprine Features
Figure 5. Mycophenolate Mofetil Features
Figure 6. Rituximab Features
Figure 7. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Devicís Syndrome (Neuromyelitis Optica) Treatment Report Years Considered
Figure 12. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2022-2027)
Figure 16. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2020
Figure 17. Global Top Devicís Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devicís Syndrome (Neuromyelitis Optica) Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue in 2020
Figure 19. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Devicís Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 23. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 24. North America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 25. United States Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 29. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 30. Europe Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 31. Germany Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2016-2027)
Figure 41. China Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Devicís Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Devicís Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 61. Teva Pharmaceuticals Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 62. Fresenius Kabi AG Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 63. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 64. Lupin Ltd. Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 65. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 66. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 67. Sandoz Inc. (Novartis) Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 68. Alkem Laboratories Ltd. Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 69. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 70. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 71. MedImmune LLC Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 72. RemeGen, Ltd. Revenue Growth Rate in Devicís Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3900
USD $5850
USD $7800
COVID-19
Offer

WHY US?

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.